A carregar...
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
IMPORTANCE: In October 2018, evolocumab was made available at a reduced annual list price of $5850 in the United States. This 60% reduction was aimed at improving patient access by lowering patient copays. Shortly thereafter, the 2018 American College of Cardiology/American Heart Association cholest...
Na minha lista:
| Publicado no: | JAMA Cardiol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551584/ https://ncbi.nlm.nih.gov/pubmed/31166576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.1647 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|